Comparison 20.
GLP‐1 agonist versus GLP‐1 agonist
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 HbA1c | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 1.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 0.33 [0.11, 0.55] |
| 1.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 0.55 [0.26, 0.84] |
| 2 HbA1c < 7% | 3 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 2.1 versus Liraglutide | 1 | 464 | Risk Ratio (M‐H, Random, 95% CI) | 0.79 [0.66, 0.96] |
| 2.2 versus Exenatide 2 mg once weekly | 2 | 511 | Risk Ratio (M‐H, Random, 95% CI) | 0.65 [0.42, 1.01] |
| 3 Hypoglycaemia | 2 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 3.1 versus Liraglutide | 1 | 467 | Risk Ratio (M‐H, Random, 95% CI) | 1.32 [0.99, 1.75] |
| 3.2 versus Exenatide 2 mg once weekly | 1 | 295 | Risk Ratio (M‐H, Random, 95% CI) | 1.13 [0.45, 2.86] |
| 4 Hypoglycaemia | Other data | No numeric data | ||
| 5 Weight change | 2 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 5.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 0.37 [‐0.55, 1.29] |
| 5.2 versus Exenatide 2 mg once weekly | 1 | 295 | Mean Difference (IV, Random, 95% CI) | 0.10 [‐1.29, 1.49] |
| 6 Weight change | Other data | No numeric data | ||
| 7 Treatment satisfaction | Other data | No numeric data | ||
| 7.1 versus Liraglutide | Other data | No numeric data | ||
| 7.2 versus Exenatide 2 mg once weekly | Other data | No numeric data | ||
| 8 Adverse events | Other data | No numeric data | ||
| 8.1 versus Liraglutide | Other data | No numeric data | ||
| 8.2 versus Exenatide 2 mg once weekly | Other data | No numeric data | ||
| 9 Systolic blood pressure | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 9.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 0.51 [‐2.72, 3.74] |
| 9.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 1.49 [‐0.71, 3.69] |
| 10 Fasting plasma glucose (mmol/L) | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 10.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 1.01 [0.46, 1.56] |
| 10.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 1.18 [1.02, 1.33] |
| 11 Post‐prandial glucose (mmol/L) | Other data | No numeric data | ||
| 11.1 versus Liraglutide | Other data | No numeric data | ||
| 11.2 versus Exenatide 2 mg once weekly | Other data | No numeric data | ||
| 12 Triglycerides (mmol/L) | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 12.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 0.18 [‐0.10, 0.46] |
| 12.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 0.01 [‐0.04, 0.06] |
| 13 Total cholesterol (mmol/L) | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 13.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 0.11 [‐0.09, 0.31] |
| 13.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 0.31 [0.10, 0.51] |
| 14 HDL‐cholesterol (mmol/L) | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 14.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | ‐0.01 [‐0.07, 0.05] |
| 14.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 0.00 [‐0.03, 0.04] |
| 15 LDL‐cholesterol (mmol/L) | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 15.1 versus Liraglutide | 1 | 464 | Mean Difference (IV, Random, 95% CI) | 0.04 [‐0.13, 0.21] |
| 15.2 versus Exenatide 2 mg once weekly | 2 | 547 | Mean Difference (IV, Random, 95% CI) | 0.20 [0.09, 0.30] |
| 16 Beta‐cell function | Other data | No numeric data |